N. ANTHONY COLES - 05 Jan 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role: CEO and Chairperson, Director
Signature: /s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 05 Jan 2023
Net transactions value: -$1,321,871
Form type: 4
Filing time: 06 Jan 2023, 16:04:19 UTC
Previous filing: 05 Jan 2023
Next filing: 08 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CERE	Common Stock	Options Exercise	$175,000	+50,000	+1849%	$3.50^*	52,704	05 Jan 2023	Direct	F1
transaction	CERE	Common Stock	Sale	$1,481,505	-49,500	-94%	$29.93	3,204	05 Jan 2023	Direct	F1, F2
transaction	CERE	Common Stock	Sale	$15,366	-500	-16%	$30.73	2,704	05 Jan 2023	Direct	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CERE	Stock Option (Right to Buy)	Options Exercise	$0	-50,000	-1.6%	$0.000000	3,002,417	05 Jan 2023	Common Stock	50,000	$3.50	Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person.
F2	The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.53 - $30.46. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3	The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.64 - $30.885. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4	25% of the shares subject to this option vested and became exercisable on November 27, 2019, with remainder vesting in 36 equal monthly installments thereafter.